Antiemetic therapy - Aphios Corporation

Drug Profile

Antiemetic therapy - Aphios Corporation

Alternative Names: Ginger extract - Aphios; Zindol

Latest Information Update: 07 Mar 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aphios Corporation
  • Developer Aphios Corporation; University of Rochester; Zindol LLC
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 07 Mar 2013 Antiemetic therapy - Aphios Corporation is available for licensing as of 07 Mar 2013. www.aphios.com
  • 04 Feb 2011 Zindol® is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top